# The Healthcare Pulse: May 22–29, 2026

> Weekly healthcare podcast intelligence brief for May 22–29, 2026. The GLP-1 story dominated: Eli Lilly's Triumph-1 retatrutide readout, Novo Nordisk CEO Mike Doustdar's comeback pitch, and Tennessee's Fair Rx Act as a structural shot at the PBMs.


## The Healthcare Pulse

### Weekly Podcast Intelligence Brief, May 22–29, 2026

```request-access
variant: ghost
heading: Want this kind of synthesis on your own coverage?
buttonText: Request access
```

## This Week at a Glance

This week's healthcare podcast conversation was overwhelmingly a **GLP-1 story**, specifically Eli Lilly's blockbuster Triumph-1 retatrutide readout (28.3% weight loss at 80 weeks) and Novo Nordisk CEO Mike Doustdar's first major sit-down framing the company's comeback. Discussion of managed care, devices, gene therapy, and broader policy was unusually thin, with the only meaningful non-obesity story being Tennessee's signing of the **Fair Rx Act** banning PBM ownership of pharmacies, a direct shot at CVS Caremark and Cigna's Express Scripts.

The newsflow tape, meanwhile, broadened the picture: Lilly announced ~$3.83B in vaccine bolt-on M&A (MT Newswires, May 26), Pfizer struck a $10.5B antibody-drug-conjugate deal with Innovent (MT Newswires, May 29), and UnitedHealth caught a wave of price target raises post-Q1 results.

---

## The People Driving the Conversation

| Speaker | Affiliation | Lens | Key Take |
| --- | --- | --- | --- |
| Mike Doustdar | CEO, Novo Nordisk | Bull on NVO comeback | UBT-251 "can" beat retatrutide; 5-year frame shifts to outcomes, not weight magnitude |
| Dr. Harlan Krumholz | Yale cardiologist | Constructive on retatrutide | "On par with bariatric surgery… on track to be approved" |
| Dr. Scott Gottlieb | Former FDA Commissioner; PFE/UNH/Illumina board | Sector strategist | Constructive on new FDA acting commissioner Diamantis; flagged GILD/MRK/REGN Ebola pipeline relevance |
| Jay Olson | Oppenheimer biotech analyst | Healthy-aging thesis | GLP-1 TAM "could prove conservative" vs. $100B+ mid-2030s consensus |
| Dave Knapp | Substack / "On The Pen" | PBM bear, multi-agonist tracker | "PBMs are an absolute parasite"; retatrutide launch "early to mid-2027" |
| Dr. John Mandrola | Medscape / TheHeart.org | Skeptic | Tirzepatide may have better efficacy/AE ratio than retatrutide; sharply critical of LivaNova's ANTHEM-HFrEF conduct |
| Dr. Karen Francavilla | Obesity medicine | Clinical translator | Wegovy HD 7.2mg "comparable" to Zepbound in completers; flagged 22% dysesthesia |
| Dr. Paul Saladino | "Heart & Soil" / Valuetainment | Pharma skeptic | "There's no biological free lunch" on GLP-1s |

**Verbatim, by speaker:**

- **Doustdar on UBT-251 vs. retatrutide:** "Based on apple-to-apple comparison of early results, I would say the short answer to your question, yes, it can" (The Journal., May 26).
- **Doustdar on the 5-year frame:** "I will promise you that 5 years from now, [weight-loss magnitude] will be part of the dialogue and not the main part… When is the last time you found a single person anywhere that you know of that died from obesity? No one dies from obesity… You die from heart attack, you die from kidney failure" (The Journal., May 26).
- **Krumholz on retatrutide:** "This is going to be a major step forward, because this is really putting the drugs on par with bariatric surgery" (Health & Veritas, May 28).
- **Jay Olson on TAM:** "Wall Street analysts forecast the total obesity and healthy aging drug market exceeding $100 billion in annual revenue by the mid-2030s. And we think that estimate could prove conservative" (Let's Talk Future, An Oppenheimer Podcast, May 26).
- **Saladino:** "When people are saying Retatrutide is the best thing since sliced bread, I'm thinking just wait… there's no biological free lunch" (Valuetainment, May 22).
- **Knapp on PBMs:** "The PBMs are an absolute parasite on our healthcare system… I don't know that our insurance system is salvageable with the people who are in the middle of it currently" (On The Pen GLP-1 News, May 26).
- **Mandrola on competitive nuance:** "It may be that tirzepatide may have a better ratio of efficacy to adverse effects" than retatrutide (This Week in Cardiology, May 22).

```request-access
variant: inline
heading: Want this kind of synthesis on your own coverage?
buttonText: Request access
```

## The Key Debates

### Debate #1, LLY Retatrutide: Generational Drug vs. "Biological Free Lunch"

**Bull side:**

- "I continue to think this is just an unbelievable growth story… Once that thing goes live, I would expect Eli Lilly to continue to do well" (Morning Market Briefing, May 22).
- 28.3% mean weight loss over 80 weeks; up to 85 lbs in BMI ≥35 extension (Health & Veritas, May 28).
- BofA raised price target to $1,251 from $1,133, citing GLP-1 U.S. sales doubling by 2033 (thefly.com, May 26).

**Bear/caution side:**

- Saladino on weight regain: "The research is pretty clear that he's going to regain the weight within one to two years. Almost all of it, and sometimes more… you are essentially committing yourself to a lifelong use of the drug" (Valuetainment, May 22).
- Mandrola flagged that GLP-1s reducing CV risk could mean "GLP-1 drugs will reduce the benefit of statins," a franchise-feedback risk (This Week in Cardiology, May 22).
- Olson on muscle loss: "Lean mass loss in middle-aged and older adults is associated with roughly a 30% increased risk of all-cause mortality" (Let's Talk Future, May 26).
- Retatrutide Phase 3 discontinuation: 11% at 12mg vs. 5% placebo, with novel skin sensation and UTI signals (Health & Veritas, May 28).

### Debate #2, NVO: CEO Comeback Story vs. Lagging Efficacy and PBM Friction

**Bull side (Doustdar himself):**

- Wegovy pill drove >1.3 million prescriptions in Q1 2026, "the best product launch in US history in volume outside of a single vaccine" with 80% new-to-brand patients (The Journal., May 26).
- Wegovy and Ozempic US list prices cut to $675/month starting 2027 (~50% / ~35% cuts), framed as TAM unlock.
- Dr. Francavilla: Wegovy HD 7.2mg ~20–21% completer weight loss is "very close, maybe comparable even, to the full dose of ZepBound, which is our most powerful anti-obesity medication right now" (The Dr. Francavilla Show, May 25).

**Bear side:**

- Doustdar conceded Redefine 4 (Kagrisema 23% vs. Zepbound 25%) wiped out "~$100 billion" in market cap in a single day.
- 22% dysesthesia rate at Wegovy HD 7.2mg vs. 6% at 2.4mg, potentially class-wide (The Dr. Francavilla Show, May 25).
- NVO Q1 EPS missed by ~85% vs. lofty consensus; gross margin contracted to 80.6%.
- Trans-Atlantic analyst split: U.S. firms at Hold/Sell (Bernstein Underperform, 175 DKK target), Nordic/European houses at Buy with targets up to 440 DKK.
- Sheldon Martin (clinic operator): "If you are new starting off, I would just dump semaglutide… We have so much newer science" (Scrubs2Estates Podcast, May 22).

### Debate #3, PBMs (CVS Caremark, Cigna/Express Scripts): Structural Disintermediation Risk

**Bear (the dominant view this week):**

- Tennessee Governor Lee signed the Fair Rx Act (May 26), the first state to ban PBM ownership of pharmacies. Knapp cited TN audits showing CVS Caremark allegedly reimbursed affiliated pharmacies "up to 16,000% more than non-affiliated pharmacies for the same medications" and Express Scripts generating "around $30 million in spread pricing revenue from Tennessee employers" (On The Pen, May 26).
- Knapp framed it as systemic: "The same entities that help determine the pricing, the reimbursement, and the access pathways to medications… are also financially benefiting from owning the pharmacies that are filling the prescriptions."
- Cash-pay / Lilly Direct / "most favored nation" pressure compounding.

**Bull / counter:** No podcast speaker this week defended the PBM model.

### Debate #4, UNH: Turnaround Inflection vs. Regulatory Overhang

**Bull side:** A cascade of price target raises followed Q1 results: UBS to $460 from $410 (May 22), Barclays to $429 from $373 (May 26), Bernstein to $492 from $444 (May 27, 27% upside), Oppenheimer to $420 from $405 (May 27). Bernstein cited a "16% adjusted EPS CAGR growth rate" justifying multiple expansion. The medical care ratio declined to 83.9%, a key signal of utilization absorption.

**Bear side:** Active DOJ probe, Medicare Advantage headwinds, and the Trump administration's anti-fraud task force temporarily halted Medicare enrollments for new home healthcare and hospice providers.

**Podcast gap:** Notably, the only UNH mention on podcasts this week was a board disclosure for Dr. Gottlieb on Squawk Pod (May 26), no fundamental commentary. The constructive analyst view here is coming from sell-side notes, not the podcast tape.

### Debate #5, Lilly's M&A Pace: Pipeline Diversification or Capital Discipline Risk?

In the past month alone, Lilly announced: up to $3.83B for Curevo / LimmaTech / Vaccine Company (May 26), up to $7B for Kelonia Therapeutics, up to $7.8B for Centessa Pharmaceuticals, and an up-to-$2.4B Orna Therapeutics deal. CSO Daniel Skovronsky framed the vaccine deals as a "deliberate strategy to prevent disease at its source rather than treat its consequences" (MT Newswires, May 26). Bulls see optionality off the GLP-1 cash engine; bears watch for execution risk as Lilly crosses the $1T market cap and integration sprawl widens.

---

## Hot Topics Under Debate

- **Retatrutide pricing strategy.** Knapp's Substack poll: ~75% expect retatrutide list >$2,000/month; ~25% expect >$4,000. Knapp's framing: "Lilly is working feverishly to get this classified as a biologic" because biologics "command upwards of $10,000 a month." But: "What exactly does Lilly want Retatrutide to become? … These goals do not coexist neatly" (On The Pen, May 26).
- **Oral GLP-1 economics.** Lilly's Foundeo (orforglipron) launched April/May 2026, no food/water restriction. But Dr. Spencer Nadolsky: "Fundeo, unfortunately, is not… cost efficient right now. I don't think enough bang for the buck," $150–$300/month DTC for ~11% weight loss (Docs Who Lift, May 25).
- **Dose-splitting and step-therapy risk to LLY revenue per patient.** Spencer Nadolsky: "Maybe we start splitting up their doses… on a 15 milligram and they're using the quick pen. Maybe they use seven and a half milligrams then, weekly and they can maintain on that." And on insurance: "We may see some things where, 'Oh, no, we're going to have to switch you to Orpho and the insurance is going to make you do it'" (Docs Who Lift, May 25).
- **Bundibugyo Ebola outbreak (900+ cases, 220+ deaths).** Gottlieb: "The risk to the United States is exceedingly low," but flagged GILD's obeldesivir + remdesivir, MRK's molnupiravir, REGN's three-antibody cocktail, and a private MAP Biotherapeutics MBP134 as relevant therapeutics. "The vaccines are at best six to nine months away. The therapeutics could be available right away" (Squawk Pod, May 26).
- **LivaNova (LNVH) ANTHEM-HFrEF failure.** Mandrola was sharply critical of the sponsor stopping enrollment early on financial grounds against DSMB recommendation; results "uninformative" due to underpowering (This Week in Cardiology, May 22).
- **MAHA pharma TV ad ban.** Bet-David and Saladino: unlikely to pass. "Big Pharma spent ~$7 billion on advertising in 2025… Pharma spending grew to 16% [of national linear TV ad spend]"; "If you eliminate the pharmaceutical ad revenue from television stations, you're going to see all the television stations collapse" (Valuetainment, May 22).
- **Pfizer–Innovent $10.5B ADC deal.** 12 early-stage cancer programs, $650M upfront, up to $9.85B in milestones plus royalties; closing in Q3 (MT Newswires, May 29). A material signal of the ADC arms race continuing.

```request-access
variant: inline
heading: Want this kind of synthesis on your own coverage?
buttonText: Request access
```

## Emerging Themes to Watch

- **"Healthy aging" as a new GLP-1 framing.** Olson highlighted that an Eli Lilly scientist described GLP-1s as "potentially the world's first longevity drug" at a major aging research conference, and Novo's CSO presented "semaglutide as a proven longevity medicine," what Olson calls "a genuine landmark moment" (Let's Talk Future, May 26). If LLY/NVO can pivot the regulatory and reimbursement narrative from "weight" to "aging," the addressable market and pricing power expand dramatically.
- **Two-tier obesity market structure.** Knapp: "Obesity medicine is slowly splitting into two Americas. You have one lane that is insurance-controlled, PBM-controlled, tightly managed access… the harder the traditional system squeezes, the more it opens up lanes for direct-to-consumer" (On The Pen, May 26). Watch the share of LLY revenue flowing through LillyDirect vs. PBM channels.
- **Multi-agonist pipeline broadening.** Knapp tracking BioMed's NA-931 (quadruple agonist, "BioGlutide"), Hanmi's HM15275 (preclinical 39.9% mouse weight loss), Shanghai Minway's MWN-109, PEP-Tango, and a quintuple agonist with data expected at ADA in June. Even modestly bullish base rates here imply LLY/NVO duopoly margins eventually compress.
- **China-sourced derisked clinical assets as a "forcing function."** SR One's Simeon George argued China is "a genuine source of high-quality, fast-executing clinical assets" and that this is reshaping the venture playbook. The Novo UBT-251 license (up to ~$2B from China's United Biotechnology) and the new Pfizer-Innovent $10.5B ADC pact are concrete data points of this thesis going mainstream.
- **Amylin / activin E / inhibin E as the next platform.** Lilly moved iloralintide (amylin) into Phase 3 (On The Pen, May 26). Olson flagged WVE and IBIO targeting activin E / inhibin E for "fat-selective, muscle-sparing weight loss," directly addressing the lean mass loss tail risk.
- **State-by-state PBM and AI healthcare regulation.** Tennessee's Fair Rx Act could be template-setting. Separately, Maine recently banned mental health providers from using AI for therapeutic communications or independent clinical decision-making; multiple states are regulating insurers' AI use in prior authorization. A material compliance headwind for digital health and managed care utilization teams.
- **GLP-1 oncology signal.** Cleveland Clinic data at ASCO (kicking off May 29) showing lower cancer metastasis rates in early-stage cancer patients on GLP-1s, plus UPenn real-world evidence indicating a 25% lower risk of breast cancer diagnoses. Gottlieb cautioned with a metformin analogy: "It didn't pan out in prospective studies. I wouldn't take the drug for that, but this could be something we ultimately discover" (Squawk Pod, May 26).

---

## Stocks on the Radar

| Ticker | Direction | Rationale |
| --- | --- | --- |
| LLY | Bullish (with valuation caution) | Triumph-1 retatrutide 28.3% weight loss; Foundeo coverage at all three major PBMs (CVS starts June 1); BofA PT to $1,251; ~$3.83B vaccine M&A; gene therapy VERVE-102 reduced LDL up to 62%. Bears flag $1T market cap and execution risk. |
| NVO | Mixed (trans-Atlantic split) | Wegovy pill best-ex-vaccine US launch by volume; UBT-251 acquired; price cuts to $675/mo in 2027. Bears: Q1 EPS miss ~85%, dysesthesia signal, lost head-to-head, Bernstein Underperform 175 DKK; bulls (Nordic): up to 440 DKK. |
| UNH | Bullish (analyst momentum) | MCR down to 83.9%; UBS $460, Barclays $429, Bernstein $492, Oppenheimer $420. Bears: active DOJ probe, MA cuts, anti-fraud task force halting some Medicare enrollments. |
| PFE | Mixed | $10.5B Innovent ADC deal; Guggenheim $36 Buy on Mevpro-1 prostate cancer optionality. Bears: BofA $27 Neutral, Wolfe $26 Underperform on revenue cliffs. |
| MRK | Bullish | EU CHMP positive opinion for Keytruda + Padcev in bladder cancer (shares +5.2% on May 22); Phase 3 sac-TMT NSCLC readout; 14.8x fwd P/E; Wells Fargo Buy $145. Bears: Keytruda LOE. |
| GILD | Bullish | First-ever FDA approval for HDV (Hepcludex) May 22; Trodelvy EU CHMP positive opinion in 1L mTNBC; Livdelzi PBC Phase 3 sustained normalization; Maxim upgrade to Buy $165. Bears: $2.74 FY26 EPS loss consensus on Tubulis acquisition. |
| ABBV | Bullish | Skyrizi/Rinvoq neutralizing Humira cliff; $15B Q1 beat; guidance raised to $14.08–$14.28 adj EPS; Maviret EU acute HCV CHMP backing; FDA approval for Decnupaz (BPDCN). Bears: 4% post-print dip on biosimilar anxiety. |
| BMY | Constructive (deep value) | UBS Buy $70, BMO target $60; milvexian AFib Phase III readout = year-end catalyst; Camzyos/Breyanzi/Reblozyl growth; Anthropic AI partnership. Bears: Revlimid/Pomalyst LOE; 15.9x P/E reflects skepticism. |
| JNJ | Mixed (defensive) | Tremfya psoriatic arthritis label expansion May 29; AI CARTOSOUND SONATA arrhythmia tool at HRS 2026; PT range $228–$252. Bears: talc litigation overhang. |
| AMGN | Mixed (binary) | MariTide Phase 3 obesity readout 2026/2027; obesity maintenance data flagged by Oppenheimer; Fitch upgrade to BBB+ after $10B Horizon debt paydown. Bears: Prolia/XGEVA/Enbrel LOE; IRA cuts; consensus PT trimmed to $352.32. |
| LNVH (LivaNova) | Bearish | ANTHEM-HFrEF VNS missed primary endpoint (HR 0.84, p=0.11); sponsor stopped enrollment early against DSMB advice. |
| CVS / CI | Bearish (structural) | Tennessee Fair Rx Act bans PBM-pharmacy ownership; allegations of 16,000% reimbursement spread and $30M spread pricing; DTC/cash-pay channels eroding gatekeeper role. |
| VKTX | Bullish (Olson) | VK2735 oral + injectable; reduces inflammatory markers, BP, reverses prediabetes, fit for "healthy aging" thesis. |
| REGN | Bullish (catalyst) | Three-antibody cocktail being used in Bundibugyo Ebola outbreak; potential commercial-trial relevance. |
| ALNY | Bullish (sell-side) | ~96.4% revenue growth; consensus PT ~$445.81 (~50% upside) on TTR and PCSK9 franchises. |
| KRYS | Bullish | VYJUVEK gene therapy granted UK authorization (12-year exclusivity); 36.5% EPS growth, 29.1% revenue growth. |
| NBIX | Bullish | $811M Q1 net product sales (+44% YoY) on INGREZZA; pending Soleno deal for VYKAT XR. |
| VCYT | Bullish | $139.1M Q1 revenue; full-year guidance raise on Afirma/Decipher volume scaling. |

```request-access
variant: inline
heading: Want this kind of synthesis on your own coverage?
buttonText: Request access
```

## Upcoming Catalysts (Next ~2 Weeks)

| Date | Event | Read-Through |
| --- | --- | --- |
| May 29, 2026 | ASCO Annual Meeting begins (Chicago) | Cleveland Clinic GLP-1/cancer metastasis data; UPenn breast cancer 25% lower risk RWE; Citizens biotech KOL dinner for CELC, RLAY, ARVN, ZYME, GILD, LLY, PFE, AZN, NVS in breast cancer |
| Jun 1, 2026 | CVS Caremark begins commercial coverage of Foundeo | Material de-risking of LLY oral GLP-1 rollout |
| Mid-June 2026 | ADA Scientific Sessions | Full Triumph-1 retatrutide dataset; "quintuple agonist" data; multiple multi-agonist updates |
| 2026 (year-end / Q4) | BMY milvexian Phase III AFib readout | UBS calls this a "major year-end catalyst that could trigger multiple expansion" |
| Late 2026 | PFE Phase 3 Mevpro-1 prostate cancer data | Guggenheim sees ~$2/share upside |
| Q3 2026 | EU final decision on ABBV Maviret (acute hep C) and other CHMP follow-throughs (Keytruda+Padcev, Trodelvy) | Multiple incremental approvals |
| 2026/2027 | AMGN MariTide Phase 3 | Binary obesity-disruption catalyst |
| 2027 (early-to-mid) | LLY retatrutide commercial launch (Knapp); LLY pricing decision (biologic vs. small molecule) | Watch for FDA approval signaling and label scope |
| Late 2026 | NVO Capital Markets Day | Pipeline update beyond obesity (NASH, CV, kidney) |
| Ongoing | Bundibugyo Ebola outbreak | GILD obeldesivir/remdesivir, MRK molnupiravir, REGN antibody cocktail in field use |

---

## The Bottom Line

The healthcare conversation this week was the GLP-1 conversation. The base case from the bulls, that Lilly continues to set the efficacy ceiling, the franchise extends into oncology and longevity, and the TAM is bigger than consensus, got real reinforcement from the Triumph-1 readout (28.3% weight loss) and from Lilly's continued ability to secure broad PBM coverage for its oral pill. The base case from the bears finally found some footholds too: a 22% dysesthesia signal in Wegovy HD that may be class-wide, an 11% retatrutide discontinuation rate at 12mg, ~25% of weight loss being lean mass, and tangible evidence that as patients persist on these drugs the dose-management economics get murkier (rescue therapy in 8% of max-dose tirzepatide patients; ATTAIN-MAINTAIN showing switchers can maintain ~75–80% of weight loss on cheaper orforglipron, which is positive for patients but mixed for LLY revenue per patient).

The most underappreciated structural story is the Tennessee Fair Rx Act and the broader two-tier obesity market thesis. If the playbook spreads, the PBM-affiliated pharmacy revenue and spread-pricing models embedded in CVS and Cigna start to face state-by-state attrition at the same time DTC/cash-pay channels (LillyDirect, NVO direct pricing at $675/mo) are eroding the gatekeeper role from the other side. That is a slow-burn fundamental thesis, not a one-week event, but it surfaced more loudly this week than at any time in recent memory.

Outside obesity, the takeaways are narrower but meaningful: UNH's turnaround narrative is being validated by the sell side (four PT raises in five days, including Bernstein to $492); Lilly's M&A pace continues to surprise with another ~$3.83B in vaccine bolt-ons; Pfizer's $10.5B Innovent ADC deal is a major signal in the China-sourced asset thesis; Merck and Gilead both racked up regulatory wins (Keytruda+Padcev in EU bladder cancer, first-ever HDV approval); AbbVie reinforced the Skyrizi/Rinvoq immunology story with a Maviret CHMP backing and a rare blood cancer approval; and LivaNova's ANTHEM-HFrEF stumble is a single-name negative for the device tape. With ASCO opening today and the ADA Scientific Sessions in mid-June, the catalyst density over the next 3–4 weeks is unusually high.

### Caveats and Data Gaps

- **Coverage skew:** Podcast coverage this week was disproportionately physician/clinician-led rather than buy-side / sell-side investor-led. We've labeled clinician sources accordingly; treat efficacy framing from clinicians as clinical, not investment-grade.
- **No podcast commentary** on UNH fundamentals, JNJ, ABBV, BMY, PFE-the-stock, MRNA, BNTX, ELV, HUM, CI (other than via PBM), CVS-the-stock (other than via PBM), TMO, DHR, A, HCA, THC, ISRG, BSX, MDT, ABT, SYK, or EW this week. We supplemented with news-tape and analyst data where available, and flagged where the podcast tape is silent.
- **MAHA and Trump healthcare policy:** Only indirect coverage, no direct podcast discussion of pharma tariffs this week, though a Department of Commerce notice on Section 232 tariff procedures was circulating in legal newsletters.
- **Pricing claims:** Sheldon Martin's retatrutide approval timeline of "November 2026" is an outlier vs. Knapp's "early to mid-2027" and Kolodzik's "early '27"; we flag the lower-confidence source.
- Some retatrutide oncology and longevity claims referenced on Morning Market Briefing (May 22) were not source-attributed; we've labeled these as unverified host claims.
- Trans-Atlantic NVO price target spread (175 DKK to 440 DKK) is unusually wide and is worth its own dedicated dive next week.

---

## Sources

- Morning Market Briefing, May 22, 2026
- Valuetainment, May 22, 2026
- This Week in Cardiology, May 22, 2026
- Scrubs2Estates Podcast, May 22, 2026
- The Dr. Francavilla Show, May 25, 2026
- Docs Who Lift, May 25, 2026
- The Journal., May 26, 2026
- Let's Talk Future, An Oppenheimer Podcast, May 26, 2026
- On The Pen GLP-1 News, May 26, 2026
- Squawk Pod, May 26, 2026
- Health & Veritas, May 28, 2026
- thefly.com, May 26, 2026
- MT Newswires, May 26, 2026
- MT Newswires, May 29, 2026

```request-access
variant: banner
heading: Run your own corpus.
description: matterfact is deployed with select institutional partners. Request access to run it on your own coverage.
buttonText: Request access
```